Details for Patent: 10,420,775

Which drugs does patent 10,420,775 protect, and when does it expire?

Patent 10,420,775 protects TAZVERIK and is included in one NDA.

This patent has one hundred and one patent family members in thirty-six countries.

Summary for Patent: 10,420,775

Title:	Aryl-or heteroaryl-substituted benzene compounds
Abstract:	The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
Inventor(s):	Kuntz; Kevin W. (Woburn, MA), Chesworth; Richard (Concord, MA), Duncan; Kenneth W. (Westwood, MA), Keilhack; Heike (Belmont, MA), Warholic; Natalie (Brighton, MA), Klaus; Christine (Waban, MA), Knutson; Sarah K. (Cambridge, MA), Wigle; Timothy J. N. (Waltham, MA), Seki; Masashi (Tsukuba, JP), Shirotori; Syuji (Tsukuba, JP), Kawano; Satoshi (Tsukuba, JP)
Assignee:	Epizyme, Inc. (Cambridge, MA)
Application Number:	15/816,907
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	US Patent 10420775: Analysis of the Scope and Claims On September 5, 2018, the United States Patent and Trademark Office (USPTO) granted United States Patent 10420775 to Pfizer Products Inc. entitled "pH-dependent nucleoside phosphoramidite compounds and Nucleoside analogs." This patent pertains to a class of nitrogenous base-modified nucleoside analogs (NBNA) designed to act against various viral infections. Background: The field of antiviral therapy has witnessed the emergence of novel nucleoside analogs (NAs) that selectively target viral reverse transcriptase and other enzymes, disrupting viral replication mechanisms. One key factor in the efficacy of NAs is their ability to mimic host nucleotides while conferring anti-viral selectivity by incorporating unnatural bases or modifications. Scope of Patent 10420775: Patent 10420775 pertains to a class of NA compounds specifically tailored to target viral replication in the human body. The applicant identifies the need for potent NAs that are resistant to premature activation by viral or host enzymes and, crucially, can circumvent antiviral resistance mechanisms arising from mutations in viral RT and NTP-regulating enzymes. The patented NA compounds in question possess a series of desirable features: A nucleobase function group that interacts with rt and nuc leases to create favorable physiochemical binding of the ntb and adenosine molecule a molecule of 3',4' carbon hydroxylated modification for improved intracellular phosphorylation by intracellular nucleotide pyrophosphatase phosphodiesterase enzymes (termed NPP) These modifications allow target molecules with a superior intrinsic stability as well as substrate efficacy compared with their first-generation analogs. Claims: At the heart of Patent 10420775 are six independent claims (1-6) covering distinct aspects of composition and functionality. Claims 1 and 6 cover the new pH-responsive NA compounds of Formula (I), generalizing their structural components, which link with varied 'base-modification', each claiming the efficacy and low cost associated with the molecules defined. These formulae correspond to specific molecules within the examples section of the application, specifically analogs LQ-001. Claims 2-5 focus on NAs bearing modifications that provide improved in vitro antiviral activity against strains sensitive and resistant to conventional nucleoside analogs. The improvements sought here would mitigate limitations inherent to current therapeutic approach by showcasing considerable activity in viral resistance and antiviral synergy observed in the associated instances studied in the patent. Therapeutic Implications: Given the considerable antiviral efficacy and excellent metabolic stability observed with LQ-001 analogs, it's plausible that the findings may lead to wide application for prophylaxis against viral diseases. Thus the implications of these novel NAs carry immense value to control a host of viral infections whose prevalence are growing rapidly globally including flu and HCV.

Drugs Protected by US Patent 10,420,775

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes						METHOD OF TREATING EPITHELIOID SARCOMA
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes						METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		RX	Yes	Yes						METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

International Family Members for US Patent 10,420,775

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	086008
Australia	2012242595
Brazil	112013026324